Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIPEL.L Regulatory News (IPEL)

  • There is currently no data for IPEL

Trading Statement

16 Dec 2013 07:00

RNS Number : 5455V
Impellam Group plc
16 December 2013
Β 

ο»Ώ

Β 

Β 

Impellam Group plc ("Impellam" or the "Company" or "Group")

Β 

Pre close trading statement

Β 

Impellam is pleased to announce that trading during the second half of the year reflects the improving economic conditions in the Group's key markets. Our staffing businesses are all expected to see year over year growth in net fees in the second half of the year with both our UK Staffing and US Staffing business seeing full year on year growth.

Β 

The Group is planning to capitalise on the opportunities available in both the managed services and specialist staffing markets. Both the UK and the US Staffing businesses are keen to accelerate investment in headcount which will lead to upward cost pressure.

Β 

Whilst we anticipate year on year growth in operating profits in both our UK and US Staffing businesses, the costs associated with both enhanced compliance requirements and the sourcing of medical professionals is still depressing net fee conversion in our Medacs business. Accordingly, Medacs will report year on year operating profit contraction in the second half, albeit at a slower rate than we saw in the first half.

Β 

The Group's staffing businesses, in total, are therefore expected to see a small year on year decrease in operating profits. However, the outlook is promising with increased activity and recovering markets.

Β 

Trading in our Carlisle Support Services business has shown some early signs of improvement. Changes to the management structure announced at the half year are starting to deliver the benefits we anticipated in the mobilisation of high volume labour solutions to the retail, transport and logistics sectors. Whilst second half trading will not show any material improvement due to restructure costs, the outlook is more favourable. However, the business has two long term contracts, one a substantial first generation out sourcing agreement, which have proven to be operationally complex, badly priced and financially onerous. In accordance with accounting standards, full provision will be made for the costs of the exiting of one and the future ongoing losses of the other. The total provision, amounting to some Β£13.0 million, will be taken as an exceptional item. Having carefully reviewed the contracts portfolio, we are satisfied that no other similar contracts exist in the Group.

Β 

Total Group adjusted operating profit is expected to be about Β£5.0 million lower than the comparative period last year.

Β 

During the year, Impellam has returned Β£19.8 million to shareholders in dividends. The return of cash to shareholders remains a key objective for the Group. A final dividend of 7.0p per share will be recommended. Further details of this will be announced in due course.

Β 

Enquiries: For further information please contact the appropriate individual below.

Β 

Β 

Impellam Group plc

Andrew Wilson

Julia Robertson

Andrew Burchall Tel: 01582 692658

Β 

Β 

Cenkos Securities plc

(Nominated Advisor and Broker to Impellam)

Nicholas Wells Tel: 020 7397 8900

Elizabeth Bowman

Β 

Β 

Note to Editors:

Β 

Impellam Group plc conducts business primarily in the UK and North America, with smaller operations in Australia, Ireland, New Zealand and mainland Europe. The Group employs nearly 6,000 people, including 2,500 managers and consultants and more than 3,500 support services workers, across a network of 230 branch and regional offices. The Group operates more than 15 specialty brands across a broad range of staffing sectors which are complemented by businesses in the outsourced support services sector. Impellam Group is ranked 17th on the Staffing Industry Analysts' 2012 Top Global Staffing Companies List.

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
TSTEXLFFXLFXFBF
Date   Source Headline
22nd Dec 201710:12 amRNSDirector/PDMR Shareholding
21st Dec 20177:00 amRNSTransaction in Own Shares
18th Dec 20177:00 amRNSShare Purchase Plan
15th Nov 20173:38 pmRNSTrading Statement
16th Oct 20177:00 amRNSDirectorate Change
2nd Oct 20174:51 pmRNSDirectorate Change
27th Jul 20177:00 amRNSHalf-year Report
28th Jun 201710:49 amRNSResult of AGM
28th Apr 20172:12 pmRNSDirector/PDMR Shareholding
16th Mar 20175:09 pmRNSAnnual Financial Report & Dividend Record Date
9th Mar 20177:00 amRNSPreliminary Results - Unaudited
15th Dec 20167:00 amRNSTrading Update
28th Jul 20167:00 amRNSHalf-year Report
29th Jun 20169:31 amRNSResult of AGM
5th May 20167:00 amRNSQ1 Trading Update
7th Apr 201611:16 amRNSHolding(s) in Company
5th Apr 20163:21 pmRNSIssue of Equity
30th Mar 20162:11 pmRNSAnnual Financial Report
9th Mar 20167:00 amRNSDividend Record Date
3rd Mar 20167:00 amRNSPreliminary Results - Unaudited
12th Jan 20168:19 amRNSTrading update and joint broker - replacement
12th Jan 20167:00 amRNSTrading update and appointment of joint broker
14th Dec 201512:15 pmRNSDirector/PDMR Shareholding
11th Dec 20158:01 amRNSTotal Voting Rights
8th Dec 20157:00 amRNSAcquisition and Trading Update
16th Nov 201511:35 amRNSResult of General Meeting
30th Oct 20157:00 amRNSPosting of Circular and Notice of General Meeting
27th Oct 20155:25 pmRNSProposed change in nature of Dividend
2nd Sep 20157:00 amRNSGrant of Options
30th Jul 20157:00 amRNSHalf Yearly Report
13th Jul 20159:00 amRNSPosting of circular
30th Jun 201510:04 amRNSResult of AGM
4th Jun 20157:00 amRNSNotice of AGM and change to dividend timetable
17th Mar 20157:00 amRNSDirector/PDMR Shareholding
9th Mar 20154:35 pmRNSIssue of Equity & Director's Shareholding
6th Mar 20159:00 amRNSAnnual Financial Report
3rd Mar 20157:00 amRNSPreliminary Results - Unaudited
16th Jan 20157:00 amRNSPre-Close Trading Update
12th Jan 20157:00 amRNSDirectorate Change
16th Dec 201410:30 amRNSDirectorate Change
13th Nov 20147:30 amRNSHolding(s) in Company
10th Nov 20141:03 pmRNSCompletion of Acquisition and Directorate Change
7th Nov 20147:00 amRNSHolding(s) in Company
4th Nov 20148:00 amRNSDirectors' Dealings
4th Nov 20147:10 amRNSPlacing to raise £15 million
4th Nov 20147:00 amRNSAcquisition of Lorien
30th Jul 20147:00 amRNSHalf Yearly Report
18th Jun 20143:44 pmRNSResult of AGM
15th May 20144:00 pmRNSDeath of a Director
7th May 20147:00 amRNSBoard Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.